title: Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation.
abstract: This study analyzes the influence of preformed DSA, identified by HLA-specific ELISA assays, on graft survival and evaluates the incidence of antibody-mediated rejection (AMR) in patients with and without pregraft desensitization. Kidney graft survival at 8 years was significantly worse in patients with DSA (n = 43) than in those without DSA (n = 194)(p = 0.03). The incidence of AMR in patients with DSA is 9-fold higher than in patients without DSA (p < 0.001) and their graft survival is significantly worse than in DSA patients without AMR and in non-DSA patients (p = 0.005). The prevalence for AMR in patients with DSA detected on historic serum is 32.3% in nondesensitized patients and 41.7% in desensitized patients. The risk for AMR is significantly more elevated in patients with strongly positive DSA (score 6-8) compared to those with DSA score 4 (p < 0.001), and in patients with historic DSA+/CXM+ compared to those with DSA+/CXM- (p = 0.01). The presence of preformed DSA is strongly associated with graft loss in kidney transplants, related to an increased risk of AMR. Our findings demonstrate the importance of detection and characterization of DSA before transplantation. Stratification of this risk could be used to determine kidney allocation and to devise specific strategies for these patients.
authors.affiliation: Department of Nephrology, Saint-Louis Hospital, Paris, France. carmen.lefaucheur@wanadoo.fr
authors.forename: C
authors.initials: C
authors.lastname: Lefaucheur
authors.forename: C
authors.initials: C
authors.lastname: Suberbielle-Boissel
authors.forename: G S
authors.initials: GS
authors.lastname: Hill
authors.forename: D
authors.initials: D
authors.lastname: Nochy
authors.forename: J
authors.initials: J
authors.lastname: Andrade
authors.forename: C
authors.initials: C
authors.lastname: Antoine
authors.forename: C
authors.initials: C
authors.lastname: Gautreau
authors.forename: D
authors.initials: D
authors.lastname: Charron
authors.forename: D
authors.initials: D
authors.lastname: Glotz
mesh_terms: D000465:Algorithms; D002102:Cadaver; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006680:HLA Antigens / Q000097:blood*; D006681:HLA-D Antigens / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007518:Isoantibodies / Q000276:immunology*; D016030:Kidney Transplantation / Q000276:immunology*; D019520:Living Donors / Q000706:statistics & numerical data; D008297:Male; D012189:Retrospective Studies; D014019:Tissue Donors / Q000706:statistics & numerical data*
chemical_list: D006680:HLA Antigens; D006681:HLA-D Antigens; D015395:Histocompatibility Antigens Class I; D007166:Immunosuppressive Agents; D007518:Isoantibodies